Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Non Operating Income (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Non Operating Income for 11 consecutive years, with -$78.9 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 2323.57% to -$78.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$63.9 million through Dec 2025, down 275.35% year-over-year, with the annual reading at $16.8 million for FY2025, 218.77% up from the prior year.
  • Non Operating Income hit -$78.9 million in Q4 2025 for Seres Therapeutics, down from $2.8 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $7.1 million in Q1 2025 to a low of -$78.9 million in Q4 2025.
  • Historically, Non Operating Income has averaged -$4.2 million across 5 years, with a median of -$246000.0 in 2021.
  • Biggest five-year swings in Non Operating Income: tumbled 2457.14% in 2022 and later surged 1309.7% in 2025.
  • Year by year, Non Operating Income stood at -$356000.0 in 2021, then soared by 794.66% to $2.5 million in 2022, then tumbled by 202.14% to -$2.5 million in 2023, then surged by 240.42% to $3.5 million in 2024, then plummeted by 2323.57% to -$78.9 million in 2025.
  • Business Quant data shows Non Operating Income for MCRB at -$78.9 million in Q4 2025, $2.8 million in Q3 2025, and $5.0 million in Q2 2025.